

PubMed

**Display Settings:** AbstractELSEVIER  
FULL-TEXT ARTICLE

*Nanomedicine*. 2013 Jun 28. pii: S1549-9634(13)00335-3. doi: 10.1016/j.nano.2013.06.010. [Epub ahead of print]

## **In vivo human time-exposure study of orally dosed commercial silver nanoparticles.**

**Munger MA, Radwanski P, Hadlock GC, Stoddard G, Shaaban A, Falconer J, Grainger DW, Deering-Rice CE.**

Department of Pharmacotherapy, University of Utah, Salt Lake City, UT, USA; Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA. Electronic address: mmunger@hsc.utah.edu.

### **Abstract**

Human biodistribution, bioprocessing and possible toxicity of nanoscale silver receive increasing health assessment. We prospectively studied commercial 10- and 32-ppm nanoscale silver particle solutions in a single-blind, controlled, cross-over, intent-to-treat, design. Healthy subjects (n=60) underwent metabolic, blood counts, urinalysis, sputum induction, and chest and abdomen magnetic resonance imaging. Silver serum and urine content were determined. No clinically important changes in metabolic, hematologic, or urinalysis measures were identified. No morphological changes were detected in the lungs, heart or abdominal organs. No significant changes were noted in pulmonary reactive oxygen species or pro-inflammatory cytokine generation. In vivo oral exposure to these commercial nanoscale silver particle solutions does not prompt clinically important changes in human metabolic, hematologic, urine, physical findings or imaging morphology. Further study of increasing time exposure and dosing of silver nanoparticulate silver, and observation of additional organ systems are warranted to assert human toxicity thresholds.

© 2013.

**Study conducted using American Biotech Labs® 10ppm and 32ppm nano silver solutions.**

**KEYWORDS:** Biological activity nanoparticles, Nanotechnology, Nanotoxicology oral ingestion, Safety research

PMID: 23811290 [PubMed - as supplied by publisher]

**LinkOut - more resources**

